# The Human Medicines Regulations 2012, Paragraph 1

Extent: E+W+S+N.I.

The following medicinal products shall be available only on prescription—
(a) a product for parenteral administration;
(b) a product that is a controlled drug as defined in section 2(1)(a) of the Misuse of Drugs Act 1971, unless it is covered by a UK marketing authorisation in which the product is classified as a pharmacy medicine or as a medicinal product subject to general sale;
(c) cyanogenic substances, other than preparations for external use;
(d) medicinal substances that on administration emit radiation, or contain or generate any substance which emits radiation, in order that radiation may be used;
(e) a product that—
(i) is covered by a UK marketing authorisation ..., Article 126a authorisation or parallel import licence in which the product is classified as a pharmacy medicine or as a medicinal product subject to general sale, and
(ii) consists of or contains aloxiprin, aspirin or paracetamol in the form of non-effervescent tablets or capsules;
(f) a product that—
(i) is covered by a UK marketing authorisation ..., Article 126a authorisation or parallel import licence in which the product is classified as a pharmacy medicine or as a medicinal product subject to general sale, and
(ii) consists of or contains (in any pharmaceutical form) pseudoephedrine salts or ephedrine base or salts; ...
(g) a product that—
(i) is not covered by a UK marketing authorisation ..., Article 126a authorisation or parallel import licence, and
(ii) is a prescription only medicine by virtue of articles 5 and 10 of, and Schedules 1 and 2 to, the Prescription Only Medicines (Human Use) Order 1997 ; ...
(h) a product which is authorised by the licensing authority on a temporary basis under regulation 174, in circumstances where the licensing authority has attached a condition to that authorisation to the effect that, for the duration of the temporary authorisation, the product is classified as a prescription only medicine ; and
(i) an EAMS medicinal product, in circumstances where the licensing authority has attached a condition to the EAMS scientific opinion in respect of that product to the effect that, for the duration of that opinion, the product is classified as a prescription only medicine.

---
Source: https://www.legislation.gov.uk/uksi/2012/1916/schedule/1/paragraph/1 (the official version)
Page: https://openlegislation.uk/human-medicines-regulations-2012/schedule-1/paragraph-1
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.